Page 33 - Read Online

Page 12 of 13 Smetanina et al. Vessel Plus 2021;5:19 https://dx.doi.org/10.20517/2574-1209.2021.17

KCNH8 as susceptibility loci. Sci Rep 2017;7:45652. DOI PubMed PMC
23. Shevela AI, Gavrilov KA, Plotnikova EY, Sevostianova KS, Filipenko ML, Smetanina MA. Altered expression of the extracellular
matrix related genes COL15A1, CHRDL2, EFEMP1, and TIMP1 in Varicose Veins. Eur J Vasc Endovasc Surg 2020;60:e75-6. DOI
24. Shadrina A, Tsepilov Y, Sokolova E, et al. Genome-wide association study in ethnic Russians suggests an association of the MHC
class III genomic region with the risk of primary varicose veins. Gene 2018;659:93-9. DOI PubMed
25. Shadrina A, Tsepilov Y, Smetanina M, et al. Polymorphisms of genes involved in inflammation and blood vessel development
influence the risk of varicose veins. Clin Genet 2018;94:191-9. DOI PubMed
26. Fukaya E, Flores AM, Lindholm D, et al. Clinical and genetic determinants of varicose veins. Circulation 2018;138:2869-80. DOI
PubMed PMC
27. Shadrina AS, Sharapov SZ, Shashkova TI, Tsepilov YA. Varicose veins of lower extremities: Insights from the first large-scale genetic
study. PLoS Genet 2019;15:e1008110. DOI PubMed PMC
28. Smetanina MA, Shadrina AS, Zolotukhin IA, Seliverstov EI, Filipenko ML. Differentially expressed genes in varicose veins disease:
current state of the problem, analysis of the Published Data. Flebol 2017;11:190. (in Russian). DOI
29. Smetanina M, Sipin F, Seliverstov E, Zolotukhin I, Filipenko M. Differentially Expressed genes in lower limb varicose vein disease.
Flebol 2020;14:122. (in Russian). DOI
30. Smetanina MA, Kel AE, Sevost'ianova KS, et al. DNA methylation and gene expression profiling reveal MFAP5 as a regulatory driver
of extracellular matrix remodeling in varicose vein disease. Epigenomics 2018;10:1103-19. DOI PubMed
31. Smetanina MA, Sipin FA, Sevostyanova KS, Khrapov EA, Zolotukhin IA, Filipenko ML. Two CpG loci in the regulatory regions of
the MFAP5 gene are hypomethylated in varicose veins. In: ABSTRACTS of the International Union of Phlebology Chapter Meeting;
2019 Aug 25-27; Krakow, Poland. Phlebological Review 2019;1:23-4.
32. Smetanina MA, Shevela AI, Gavrilov KA, Filipenko ML. Modified methylation of the DNA loci related to the genes HRC, DPEP2,
and CCN5 in varicose veins. In: BOOK OF ABSTRACTS of the 13th St. Petersburg Venous Forum (Christmas Meetings); 2020 Dec
4-5; St. Petersburg, Russia. ADVANCED PROBLEMS IN PHLEBOLOGY; 2020. p. 11-12.
33. Lim JP, Brunet A. Bridging the transgenerational gap with epigenetic memory. Trends Genet 2013;29:176-86. DOI PubMed PMC
34. Legoff L, D'Cruz SC, Tevosian S, Primig M, Smagulova F. Transgenerational Inheritance of Environmentally Induced Epigenetic
Alterations during Mammalian Development. Cells 2019;8:1559. DOI PubMed PMC
35. Bradbury J. Human epigenome project--up and running. PLoS Biol 2003;1:E82. DOI PubMed PMC
36. Ashar FN, Zhang Y, Longchamps RJ, et al. Association of mitochondrial DNA copy number with cardiovascular disease. JAMA
Cardiol 2017;2:1247-55. DOI PubMed PMC
37. Smetanina MA, Sevost’ianova KS, Shirshova AN, et al. Quantitative and structural characteristics of mitochondrial DNA in varicose
veins. In: SCIENTIFIC PROGRAMME AND BOOK OF ABSTRACTS of the 20th Annual Meeting of the European Venous Forum;
2019 June 27-29; Zurich, Switzerland. Edizioni Minerva Medica;24.
38. Castellani CA, Longchamps RJ, Sumpter JA, et al. Mitochondrial DNA copy number can influence mortality and cardiovascular
disease via methylation of nuclear DNA CpGs. Genome Med 2020;12:84. DOI PubMed PMC
39. Kharkevich DA. Venotropic (phlebotropic) agents. Eksp Klin Farmakol 2004;67:69-77. (in Russian) [PMID: 15079914] PubMed
40. Felixsson E, Persson IA, Eriksson AC, Persson K. Horse chestnut extract contracts bovine vessels and affects human platelet
aggregation through 5-HT(2A) receptors: an in vitro study. Phytother Res 2010;24:1297-301. DOI PubMed
41. Feldo M, Wójciak-Kosior M, Sowa I, et al. Effect of Diosmin Administration in Patients with Chronic Venous Disorders on Selected
Factors Affecting Angiogenesis. Molecules 2019;24:3316. DOI PubMed PMC
42. Ivanov V, Roomi MW, Kalinovsky T, Niedzwiecki A, Rath M. Bioflavonoids effectively inhibit smooth muscle cell-mediated
contraction of collagen matrix induced by angiotensin II. J Cardiovasc Pharmacol 2005;46:570-6. DOI PubMed
43. Zheng Y, Zhang R, Shi W, et al. Metabolism and pharmacological activities of the natural health-benefiting compound diosmin. Food
Funct 2020;11:8472-92. DOI PubMed
44. Coccheri S, Mannello F. Development and use of sulodexide in vascular diseases: implications for treatment. Drug Des Devel Ther
2013;8:49-65. DOI PubMed PMC
45. Zolotukhin IA, Porembskaya OY, Smetanina MA, Sazhin AV, Filipenko ML, Kirienko AI. Varicose veins: on the verge of discovering
the cause? Annals RAMS 2020;75:36-45. (in Russian). DOI
46. Maggioli A. Chronic venous disorders: pharmacological and clinical aspects of micronized purified flavonoid fraction.
Phlebolymphology 2016;23:82-91.
47. Ramelet AA. Venoactive Drugs. In: Goldman MP, Weiss RA, editors. Sclerotherapy 6th ed. Treatment of Varicose and Telangiectatic
Leg Veins. Elsevier; 2017. pp. 426-34. DOI
48. Mansilha A, Sousa J. Pathophysiological Mechanisms of Chronic Venous Disease and Implications for Venoactive Drug Therapy. Int
J Mol Sci 2018;19:1669. DOI PubMed PMC
49. Paysant J, Sansilvestri-Morel P, Bouskela E, Verbeuren TJ. Different flavonoids present in the micronized purified flavonoid fraction
(Daflon 500 mg) contribute to its anti-hyperpermeability effect in the hamster cheek pouch microcirculation. Int Angiol 2008;27:81-5.
[PMID: 18277344]. PubMed
50. Yanushko VA, Bayeshko AA, Sushkov SA, Nebylitsyn YS, Nazaruk AM. Benefits of MPFF on primary chronic venous disease-
related symptoms and quality of life: the DELTA study. Phlebolymphology 2014;21:146-51.
51. Graças C de Souza M, Cyrino FZ, de Carvalho JJ, Blanc-Guillemaud V, Bouskela E. Protective Effects of Micronized Purified
Flavonoid Fraction (MPFF) on a Novel Experimental Model of Chronic Venous Hypertension. Eur J Vasc Endovasc Surg
2018;55:694-702. DOI PubMed